Cidara TherapeuticsCDTX
CDTX
About: Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Employees: 73
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
416% more capital invested
Capital invested by funds: $35.6M [Q3] → $184M (+$148M) [Q4]
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
200% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]
50.5% more ownership
Funds ownership: 47.0% [Q3] → 97.5% (+50.5%) [Q4]
48% more funds holding
Funds holding: 27 [Q3] → 40 (+13) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
79%
upside
Avg. target
$39
98%
upside
High target
$46
136%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Citizens Capital Markets Roy Buchanan 23% 1-year accuracy 6 / 26 met price target | 136%upside $46 | Market Outperform Initiated | 12 Mar 2025 |
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 67 / 155 met price target | 79%upside $35 | Buy Maintained | 10 Mar 2025 |
Needham Joseph Stringer 20% 1-year accuracy 24 / 122 met price target | 79%upside $35 | Buy Reiterated | 7 Mar 2025 |
Financial journalist opinion
Based on 5 articles about CDTX published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 week ago
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the “Other pharmaceuticals as preventive tools” panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled “What research is important to prepare and respond to H5N1 influenza outbreaks,” will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT.
Neutral
GlobeNewsWire
2 weeks ago
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada.
Neutral
GlobeNewsWire
2 weeks ago
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status
Neutral
GlobeNewsWire
3 weeks ago
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates.
Neutral
GlobeNewsWire
1 month ago
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization
Positive
Seeking Alpha
1 month ago
Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388's safety and efficacy. CD388 inhibits viral replication and activates the immune response, and its mechanism of action actually received the FDA's Fast Track designation.
Neutral
GlobeNewsWire
2 months ago
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference.
Positive
Zacks Investment Research
3 months ago
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Cidara Therapeutics, Inc. (CDTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CDTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Positive
Seeking Alpha
4 months ago
Cidara: Potential To Change Flu Prophylaxis Landscape With CD388
Results from phase 2b NAVIGATE study, using CD388 as a prophylaxis for Flu, expected to be released Q3 of 2025. CD388 offers broad influenza A and B coverage regardless of strain type and even effective in immunocompromised patients, and could revolutionize flu treatment. The global influenza vaccine market is projected to grow to $17.77 billion by 2032.
Charts implemented using Lightweight Charts™